8-K: Crinetics Pharmaceuticals to Unveil Extensive Clinical Data at ENDO 2025, Highlighting Progress in Endocrine Pipeline

Crinetics Pharmaceuticals announced it will present eight abstracts, including long-term efficacy and safety data for PALSONIFY and Phase 2 results for atumelnant, at the upcoming Endocrine Society's Annual Meeting, ENDO 2025.

Summary

• Crinetics Pharmaceuticals will present eight abstracts from its novel clinical development programs at the Endocrine Society's Annual Meeting, ENDO 2025, taking place from July 12-15, 2025, in San Francisco, California.
• Four abstracts will report results from the PALSONIFY (paltusotine) development program for acromegaly, including open-label extension data from the registrational Phase 3 PATHFNDR trials, highlighting long-term efficacy, safety, and symptom control in patients switching from injectable somatostatin receptor ligands (SRLs) to once-daily oral PALSONIFY.
• Three abstracts will be presented from the atumelnant clinical development program for congenital adrenal hyperplasia (CAH), including oral presentation of Phase 2 trial results, focusing on reductions in adrenal volume and rapid, sustained reductions in potent 11-oxygenated androgens.
• New data from an early-stage pipeline program, CRN12755, for Graves hyperthyroidism and orbitopathy will also be featured.
• PALSONIFY is an investigational once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist that has completed Phase 3 clinical development for acromegaly and is in Phase 3 clinical development for carcinoid syndrome.
• Atumelnant is the first once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal gland, currently in development for CAH and ACTH-dependent Cushing's syndrome.

Sentiment

Score: 8

Explanation: The document conveys a highly positive sentiment, emphasizing strong clinical data for lead candidates, a deep and innovative pipeline, and significant progress towards addressing unmet medical needs in endocrine diseases. The tone is confident and forward-looking, highlighting successful trial results and upcoming presentations at a major industry conference.

Positives

• Presentation of eight abstracts at a major endocrine conference (ENDO 2025) demonstrates significant progress and breadth of pipeline.
• Long-term efficacy and safety data for PALSONIFY in acromegaly continue to support a durable, consistent response profile, including biochemical and symptom control, and a well-tolerated safety profile.
• Compelling Phase 2 trial results for atumelnant in CAH show rapid, substantial, and sustained reductions in key disease-related biomarkers, including androstenedione, 17-hydroxyprogesterone, and 11-oxygenated androgens.
• New data from an early-stage pipeline program (CRN12755 for Graves hyperthyroidism and orbitopathy) indicates continued innovation and potential for addressing additional unmet needs.
• PALSONIFY is positioned as the first investigational once-daily, oral, selectively-targeted SST2 nonpeptide agonist to complete Phase 3 for acromegaly, offering a significant convenience advantage over injectable therapies.
• Atumelnant is noted as the first once-daily, oral ACTH receptor antagonist, representing a novel therapeutic approach for CAH and ACTH-dependent Cushing's syndrome.

Risks

• Initial or topline data reported may change following completion or a more comprehensive review of the data related to clinical studies, and such data may not accurately reflect the complete results of a clinical study.
• The FDA and other regulatory authorities may not agree with Crinetics' interpretation of clinical study results.
• Geopolitical events may disrupt Crinetics' business and that of the third parties on which it depends, potentially delaying or otherwise disrupting clinical and preclinical studies, manufacturing and supply chain, or impairing employee productivity.
• The success of Crinetics' clinical studies and nonclinical studies is not guaranteed.
• Regulatory developments in the United States and foreign countries could impact the development and approval process.
• Clinical studies and preclinical studies may not proceed at the time or in the manner expected, or at all.
• The timing and outcome of research, development, and regulatory review are uncertain, and Crinetics' drug candidates may not advance in development or be approved for marketing.

Future Outlook

Crinetics anticipates continued progress in the clinical development of atumelnant and paltusotine, including their therapeutic potential, clinical benefits, and safety profiles. The company also outlines plans and timelines for the commercial launch of PALSONIFY if approved, and the potential clinical benefits of its TSHR antagonist, CRN12755, across multiple indications, along with the anticipated timing of future clinical trials and registration applications for its development candidates.

Management Comments

• "ENDO 2025 will be an incredibly meaningful moment for Crinetics in our mission to be the premier endocrine-focused global pharmaceutical company." Scott Struthers, Ph.D., Founder and Chief Executive Officer.
• "For our lead investigational candidate PALSONIFY for acromegaly, we are excited to present long-term data that continue to support the durable, consistent response profile it has shown in earlier pivotal trials." Scott Struthers, Ph.D.
• "Additionally, compelling Phase 2 trial results from atumelnant in CAH and new data from one of our early-stage development programs demonstrate that the Crinetics pipeline can address significant unmet needs." Scott Struthers, Ph.D.

Industry Context

Crinetics Pharmaceuticals is positioning itself as a leader in the treatment of endocrine diseases, focusing on developing novel, orally delivered small molecule therapies. The upcoming presentations at ENDO 2025 underscore its commitment to addressing significant unmet medical needs in conditions such as acromegaly, congenital adrenal hyperplasia (CAH), and Graves disease. The emphasis on oral, once-daily formulations like PALSONIFY and atumelnant represents a potential shift in treatment paradigms, offering improved patient convenience compared to existing injectable therapies and introducing novel mechanisms of action.

Comparison to Industry Standards

• PALSONIFY is designed as a once-daily oral option for acromegaly, which offers a significant convenience advantage over current monthly injectable somatostatin receptor ligands (SRLs), potentially improving patient adherence and quality of life.
• Atumelnant is highlighted as the first once-daily, oral ACTH receptor antagonist, representing a novel mechanism of action for diseases like CAH and ACTH-dependent Cushing's syndrome, potentially offering a new therapeutic pathway where current options may be limited or suboptimal.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, pipeline progress, and upcoming presentations, potentially increasing investor confidence and share price.
• Patients: Potential for improved treatment options, particularly with an oral, once-daily option for acromegaly (PALSONIFY) and a novel mechanism for CAH (atumelnant), addressing unmet needs and improving quality of life.
• Employees: Positive impact from company progress and potential for future growth and commercialization.

Next Steps

• Presentations at the Endocrine Society's Annual Meeting, ENDO 2025, from July 12-15, 2025.
• Continued clinical development of atumelnant and paltusotine.
• Commercial launch of PALSONIFY if approved.
• Anticipated timing of clinical trials and registration applications for development candidates.
• Ongoing enrollment for the Phase 3 CALM-CAH trial and a Phase 1/2b trial in ADCS for atumelnant.

Key Dates

Recommendation

Keywords

Crinetics Pharmaceuticals, CRNX, PALSONIFY, paltusotine, atumelnant, CRN12755, acromegaly, congenital adrenal hyperplasia, CAH, Graves hyperthyroidism, orbitopathy, endocrine diseases, clinical development, Phase 3, Phase 2, ENDO 2025, somatostatin receptor type 2 agonist, ACTH receptor antagonist, pharmaceutical, biotechnology